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Long-term efﬁcacy and safety of dasatinib
in patients with chronic myeloid leukemia
in accelerated phase who are resistant to
or intolerant of imatinib
Oliver Ottmann1, Giuseppe Saglio2, Jane F. Apperley3, Christopher Arthur4, Eduardo Bullorsky5, Aude Charbonnier6,
John F. Dipersio7, Hagop Kantarjian8, Hanna Jean Khoury9, Dong-Wook Kim10, Diane Healey11, Lewis Strauss11 and
Jorge E. Cortes8
Treatment with a frontline BCR-ABL1 tyrosine kinase
inhibitor (TKI; e.g., imatinib, dasatinib, and nilotinib)
allows patients with chronic myeloid leukemia (CML) in
chronic phase (CP) to achieve a near normal life expec-
tancy1, whereas treatment for CML in accelerated phase
(AP) is more problematic. While reports describe out-
comes for patients with CML-AP at initial diagnosis2,3,
outcomes have been historically worse once CP disease
has progressed to AP. Approximately 50% of patients with
CML-AP who receive imatinib as initial treatment
develop imatinib resistance4 and experience disease pro-
gression5. Second-generation TKIs are indicated for
patients with CML-CP or advanced CML resistant to/
intolerant of prior therapy (including imatinib)6. After
initial approval of dasatinib twice a day (BID) for the
treatment of patients with CML resistant to/intolerant of
imatinib in all stages, this phase 3 CA180-035 study
(NCT00123487) was developed to investigate once (QD)
or twice (BID) a day dasatinib treatment in patients with
CML-AP, CML in blast phase, or Ph+ acute lympho-
blastic leukemia resistant to/intolerant of imatinib.
Patients were randomized to receive dasatinib at either
70mg BID (the standard dose at the time) or 140 mg QD.
Comparison of major hematologic response (MaHR)
between the dosage arms was the primary objective;
MaHR included either a complete hematologic response
(CHR) or no evidence of leukemia. Data from the 1-year
and 2-year study reports (patients with 6.5 and 15 months’
median follow-up, respectively) noted that patients with
CML-AP in the QD or BID arms obtained similar MaHR
and major cytogenetic responses4,7. Patients who did not
progress, die, or withdraw consent were followed for at
least 7 years from the study start. Following the primary
analysis after 2 years of the study, long-term safety out-
comes in patients with clinical beneﬁt who remained on
study became the primary objective. Subsequently, efﬁ-
cacy, as deﬁned by MaHR, was assessed 5 years after the
study start, and safety data and date/cause of death were
collected out to 7 years. The majority of the patients who
remained on study at 2 years were in the CML-AP cohort
(110/128; [86%]). Long-term efﬁcacy and safety data,
beyond 2 years, had not previously been reported in these
patients with CML-AP, warranting additional follow-up.
As previously described, patients were diagnosed with
CML-AP based on the standard deﬁnition (i.e., hemato-
logic criteria4 or clonal evolution); patients with pro-
gression of a prior CML-AP diagnosis after achieving a
hematologic response were also eligible4. Clonal evolution
included additional chromosomal abnormalities besides
the Ph chromosome (e.g., +8, +19, iso17q)8. After 2 years,
patients who experienced-speciﬁc AEs (e.g., any-grade
recurring ﬂuid retention, including pleural and/or peri-
cardial effusion, or any-grade gastrointestinal bleed
despite dose reduction by one level) were allowed to
switch from BID to QD dosing, but data were analyzed
based on the initial randomization arm. After 2 years, 28
of 57 patients with CML-AP switched from BID to QD
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dosing and 6 patients switched from QD to BID dosing
(Supplementary Table 1), limiting comparisons between
the dosage arms made after 2 years.
Of 611 randomized patients, 317 (52%) were diagnosed
with CML-AP at baseline and form the focus of this
report. Forty (13%) patients continued to receive the
treatment beyond 5 years. The most common reasons for
discontinuation were study-drug toxicity (QD: 29%; BID:
36%) or disease progression (QD: 27%; BID: 23%). The
median duration of dasatinib for patients with CML-AP
was 15 months (QD) or 13 months (BID) at the 5-year
cutoff (Table 1). At 7 years, the average daily dose of
dasatinib was similar for patients enrolled based on
hematologic criteria, clonal evolution, or prior diagnosis
of CML-AP (Table 1).
The rate of MaHR by 5 years (QD: 67%; BID: 69%) was
consistent with the 15-month report4, suggesting that
most patients may have reached maximum response by
15 months. The median duration of response in patients
with MaHR was 54 months at 5 years for the QD arm and
55 months for the BID arm (Fig. 1). Progression due to
loss of hematologic response slightly increased in both the
QD and BID dosage arms from 12% and 14%, respectively,
at 2 years to 15% in both arms at 5 years. The best
response of CHR at any time within 5 years was reached
in 51% and 54% of patients in the QD and BID arms,
respectively.
Dose schedule did not appear to affect 5-year rates of
progression-free survival (PFS) in patients with CML-AP
(Table 1 and Fig. 1). Patients with clonal evolution at
enrollment had a numerically higher 5-year PFS rate (42%
in both arms) compared to patients diagnosed based on
hematologic status (21% in both arms) or having a prior
diagnosis of CML-AP (QD: 31%; BID: 24%) (Table 1).
Five-year overall survival (OS) rates were numerically
higher in patients who were assigned BID versus QD
dosing (Fig. 1) whether diagnosis was based on hemato-
logic status (46% vs. 33%), clonal evolution (68% vs. 53%),
or prior diagnosis of AP (60% vs. 54%) (Table 1). Although
5-year OS rates were higher for the BID versus QD arm,
the hazard ratio (HR; 1.37 [conﬁdence interval:
0.99–1.90]) suggests comparable effects.
After 7 years of follow-up, 83 of 157 (53%) and 67 of 160
(42%) patients had died in the QD and BID arms,
respectively, 25 (15%) and 17 (11%) within 30 days of their
last dasatinib dose. Only one patient died due to study-
drug toxicity; the patient was enrolled into the QD arm
and died at <2 years on study.
Data relating to the presence or absence of mutations at
baseline and at the end of treatment/disease progression
were available for a total of 61 (QD) and 58 (BID) patients
at 5 years. The treatment arms had a similar proportion of
patients with no identiﬁed mutations at baseline (QD:
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BID: 50%). Over the course of 5 years, 16 patients (QD: 10;
BID: 6) with no mutation at baseline had a new mutation
identiﬁed. The most common acquired mutations were
T315I (QD: 9; BID: 10) and F317L (QD: 5; BID: 4).
Conversely, of patients with an identiﬁed baseline muta-
tion (QD: 25; BID: 28), the mutation was no longer
detected at 5 years in nine patients (QD: 4; BID: 5). The
most frequently lost mutations were E255K in the BID
arm (n= 5) and M351T in the QD arm (n= 4).
With respect to treatment-related AEs after 5 years of
follow-up (Supplementary Fig. 1), any-grade treatment-
related ﬂuid retention events occurred more frequently in
the BID (53%) versus QD (40%) arm. Treatment-related
pleural effusion events of any grade slightly increased in
incidence between 2 years (QD: 31 [20%]; BID: 62 [39%])
and 5 years (QD: 43 [27%]; BID: 71 [44%]); grade 3–5
pleural effusion occurred in 14 (9%) and 15 (9%) patients in
the QD and BID arms, respectively, at 5 years. While the
incidence of pleural effusion was unchanged between 5 and
7 years in this study population, others have reported a
continuing risk over time after years of dasatinib treatment9.
At 5 years, there were four cases (two grade 3–5) of
drug-related congestive heart failure/cardiac dysfunction
in patients in the BID arm. Drug-related pulmonary
hypertension was diagnosed by echocardiogram in three
patients and indicated by X-ray in one case; it was
observed in one (grade 3–5) and three (grade 1–2)
patients in the QD and BID arms, respectively, within 5
years. The case in the QD arm was diagnosed on study
day 944 and the cases in the BID arm were diagnosed on
study days 36, 463, and 838. There were no cases of
pulmonary arterial hypertension (PAH); however, right
heart catheterization is required to conﬁrm PAH, and
only one procedure was performed.
The frequency of hematologic and biochemical AEs was
similar between the two dosage groups and was consistent
with the earlier study report4. No new safety signals were
identiﬁed in patients who remained on treatment after the
5-year cutoff.
Data from the CA180-035 trial represent the largest study
to date, with the longest follow-up, of dasatinib-treated
patients with CML-AP. After 5 years of treatment, rates of
MaHR, PFS, and OS in the QD and BID dosing arms
suggest comparable efﬁcacy with either regimen. Main-
tenance of MaHR suggests that some patients with CML-
AP, who are responding well to second-line dasatinib
therapy and are at high risk for transplant-related mortality
may not need to seek a stem cell transplant. More AEs,
speciﬁcally ﬂuid-retention events (e.g., pleural effusion),
occurred in patients with CML-AP in the BID versus QD
arm. The reason for higher OS in the BID arm is unclear.
However, because there is no signiﬁcant difference in sur-
vival between these dosages, BID dosing has a more com-
plicated safety proﬁle, and patients with CML-AP who
respond to and tolerate dasatinib treatment can maintain
long-term responses, the data reinforce the current QD
dose indication for treatment of patients with advanced
CML. Overall, the 5-year efﬁcacy and 7-year safety data in
dasatinib-treated patients after imatinib intolerance/resis-
tance presented here support use of dasatinib for long-term
treatment of patients diagnosed with CML-AP.
Fig. 1 Efﬁcacy outcomes for patients with CML-AP by dosing
schedule. a Duration of MaHR for patients who achieved MaHR, b
PFS, and c OS are shown for the QD (solid lines) and BID (dashed lines)
dosing groups. Efﬁcacy analyses were conducted in the intention-to-
treat population of patients. BID twice a day, CI conﬁdence interval,
MaHR major hematologic response, NA not available, OS overall
survival, PFS progression-free survival, QD once a day
Ottmann et al. Blood Cancer Journal  (2018) 8:88 Page 3 of 4
Blood Cancer Journal
Acknowledgements
The authors would like to thank all participating study sites for this Bristol-
Myers Squibb–sponsored analysis. Professional medical writing and editorial
assistance were provided by Kelly M. Fahrbach, PhD, of StemScientiﬁc, an
Ashﬁeld Company, part of UDG Healthcare plc, funded by Bristol-Myers
Squibb. The authors did not receive ﬁnancial compensation from Bristol-Myers
Squibb for authoring this manuscript.
Author details
1Cardiff University, Cardiff, Wales, UK. 2University of Turin, Turin, Italy. 3Imperial
College, London, UK. 4Royal North Shore Hospital, Sydney, NSW, Australia.
5Hospital Britanico, Buenos Aires, Argentina. 6Institut Paoli-Calmettes, Marseille,
France. 7Washington University School of Medicine, St. Louis, MO, USA. 8The
University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9Winship
Cancer Institute, Emory University, Atlanta, GA, USA. 10Catholic Hematology
Hospital, Seoul St. Mary’s Hospital, Leukemia Research Institute, The Catholic
University of Korea, Seoul, South Korea. 11Bristol-Myers Squibb, Princeton, NJ,
USA
Author contributions
All authors provided feedback and guidance on the analysis and interpretation
of the results, critically reviewed and provided revisions to the manuscript, and
approved the ﬁnal draft for submission.
Conﬂict of interest
O.O. has acted as a consultant, advisor, or speaker for ARIAD, Bristol-Myers
Squibb, Celgene, Fusion Pharma, Novartis, Pﬁzer, Roche, and SUN Pharma. G.S.
has acted as a consultant and a speaker for ARIAD, Bristol-Myers Squibb,
Novartis, and Pﬁzer. J.F.A. is an NIHR Senior Investigator and acknowledges the
support of the Imperial College NIHR Biomedical Research Centre and has
acted as a consultant, speaker, and advisor for ARIAD, Bristol-Myers Squibb,
Incyte, Novartis, Pﬁzer, and SUN Pharma. C.A. has served on advisory boards
and acted as a speaker for ARIAD, Bristol-Myers Squibb, Novartis, and Pﬁzer. E.B.
has no disclosures to declare. A.C. has served on advisory boards and has acted
as a speaker for Bristol-Myers Squibb, Incyte, Novartis, and Pﬁzer. J.F.D. has no
disclosures to declare. H.K. has served on advisory boards for ARIAD, Bristol-
Myers Squibb, Novartis, and Pﬁzer. H.J.K. has no disclosures to declare. D.-W.K.
has received research funding from and served on an advisory committee for
Bristol-Myers Squibb. D.H. and L.S. are employees of Bristol-Myers Squibb. J.C.
has served as a consultant to and received research funding from ARIAD,
Bristol-Myers Squibb, Novartis, Pﬁzer, and Teva.
Data-sharing statement The Bristol-Myers Squibb policy on data sharing
may be found at https//www.bms.com/researchers-and-partners/
independent-research/data-sharingrequest-process.html.
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41408-018-0122-3).
Electronic supplementary material
Supplementary Information accompanies this paper at (https://doi.org/
10.1038/s41408-018-0122-3).
Data-sharing statement The Bristol-Myers Squibb policy on data sharing
may be found at https://www.bms.com/researchers-and-partners/
independent-research/data-sharingrequest-process.html.
Received: 4 April 2018 Accepted: 12 June 2018
References
1. Sasaki, K. et al. Relative survival in patients with chronic-phase chronic myeloid
leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six
prospective clinical trials. Lancet Haematol. 2, e186–e193 (2015).
2. Ohanian, M. et al. Tyrosine kinase inhibitors as initial therapy for patients with
chronic myeloid leukemia in accelerated phase. Clin. Lymphoma Myeloma Leuk.
14, 155–162 (2014). e1.
3. Rea, D. et al. First-line imatinib mesylate in patients with newly
diagnosed accelerated phase-chronic myeloid leukemia. Leukemia 26,
2254–2259 (2012).
4. Kantarjian, H. et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg
twice daily in patients with chronic myeloid leukemia in accelerated phase
resistant or intolerant to imatinib: 15-month median follow-up. Blood 113,
6322–6329 (2009).
5. Radich, J. Major progress in understanding progression in chronic myeloid
leukemia. J. Exp. Med. 212, 1482 (2015).
6. Sprycel (dasatinib) [package insert]. (Princeton, NJ: Bristol-Myers Squibb, 2015).
7. Pasquini, R. et al. Dasatinib 140 mg QD compared to 70 mg BID in advanced-
phase CML or Ph(+) ALL resistant or intolerant to imatinib: one-year results of
CA180–035. Presented at: American Society of Clinical Oncology, (Chicago,
Illinois, 2007) abstr. 7025.
8. Tarkan-Arguden, Y. et al. Cytogenetic clonal evolution in patients with chronic
myeloid leukemia. Biotechnol. Biotechnol. Equip. 23, 1515–1520 (2014).
9. Shah, N. P. et al. Dasatinib in imatinib-resistant or -intolerant chronic-phase,
chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. Am. J.
Hematol. 91, 869–874 (2016).
Ottmann et al. Blood Cancer Journal  (2018) 8:88 Page 4 of 4
Blood Cancer Journal
